Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Spruce Biosciences Inc (NQ: SPRB )

2.340 UNCHANGED
Streaming Delayed Price Updated: 3:59 PM EDT, Jun 6, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Spruce Biosciences Inc

< Previous 1 2 Next >
Spruce Biosciences Appoints Percival Barretto-Ko to Board of Directors
From Spruce Biosciences, Inc.
Via Business Wire
Spruce Biosciences to Participate in the Jefferies Healthcare Conference
From Spruce Biosciences, Inc.
Via Business Wire
Spruce Biosciences Honored at CARES Foundation 15th Annual Everyone CARES Gala
From Spruce Biosciences, Inc.
Via Business Wire
Spruce Biosciences Reports First Quarter 2023 Financial Results and Provides Corporate Updates
From Spruce Biosciences, Inc.
Via Business Wire
Spruce Biosciences to Present Findings on Retrospective Analysis of Completion Rates for CAH Studies at Pediatric Endocrine Society 2023 Annual Meeting
From Spruce Biosciences, Inc.
Via Business Wire
Spruce Biosciences to Participate in May Investor Conferences
From Spruce Biosciences, Inc.
Via Business Wire
Spruce Biosciences Reports Full Year 2022 Financial Results and Provides Corporate Updates
From Spruce Biosciences, Inc.
Via Business Wire
Spruce Biosciences to Participate in the Oppenheimer 33rd Annual Healthcare Conference
From Spruce Biosciences, Inc.
Via Business Wire
Spruce Biosciences Announces $53.6 Million Private Placement Financing
From Spruce Biosciences, Inc.
Via Business Wire
Spruce Biosciences to Participate in the SVB Securities Global Biopharma Conference
From Spruce Biosciences, Inc.
Via Business Wire
Spruce Biosciences Provides Clinical Program Updates and Outlines Anticipated Milestones for 2023
From Spruce Biosciences, Inc.
Via Business Wire
Spruce Biosciences (NASDAQ: SPRB) Enters Into Collaboration with Kaken Pharmaceutical to Develop Tildacerfont for CAH in Japan
Spruce Biosciences, Inc. (NASDAQ: SPRB) is engaged as a late-stage biopharmaceutical company, which is focused on the research, development and 
Via Spotlight Growth
Spruce Biosciences and Kaken Pharmaceutical Announce Strategic Partnership and Exclusive Licensing Agreement to Develop and Commercialize Tildacerfont for CAH in Japan
From Spruce Biosciences, Inc.
Via Business Wire
Spruce Biosciences Reports Third Quarter 2022 Financial Results and Provides Corporate Updates
From Spruce Biosciences, Inc.
Via Business Wire
Spruce Biosciences to Participate in November Investor Conferences
From Spruce Biosciences, Inc.
Via Business Wire
Spruce Biosciences to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
From Spruce Biosciences, Inc.
Via Business Wire
Spruce Biosciences Reports Second Quarter 2022 Financial Results and Provides Corporate Update
From Spruce Biosciences, Inc.
Via Business Wire
Spruce Biosciences to Participate in June Investor Conferences
From Spruce Biosciences, Inc.
Via Business Wire
Spruce Biosciences Announces Acceptance of Abstract for Presentation at ENDO 2022 Annual Conference
From Spruce Biosciences, Inc.
Via Business Wire
Spruce Biosciences Reports First Quarter 2022 Financial Results and Provides Corporate Update
From Spruce Biosciences, Inc.
Via Business Wire
Spruce Biosciences to Participate in May Investor Conferences
From Spruce Biosciences, Inc.
Via Business Wire
Spruce Biosciences Appoints Libbie Mansell, Ph.D., M.B.A., R.A.C., as Chief Regulatory and Quality Officer
From Spruce Biosciences, Inc.
Via Business Wire
Spruce Biosciences Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Updates
From Spruce Biosciences, Inc.
Via Business Wire
Spruce Biosciences Appoints Will Charlton, M.D., M.A.S., as Chief Medical Officer
From Spruce Biosciences, Inc.
Via Business Wire
Spruce Biosciences to Participate in the SVB Leerink 11th Annual Global Healthcare Conference
From Spruce Biosciences, Inc.
Via Business Wire
Spruce Biosciences Provides Clinical Program Updates and Outlook for 2022
From Spruce Biosciences, Inc.
Via Business Wire
Spruce Biosciences Appoints Javier Szwarcberg, M.D., MPH as Chief Executive Officer
From Spruce Biosciences, Inc.
Via Business Wire
Spruce Biosciences to Participate in the Piper Sandler 33rd Annual Healthcare Conference
From Spruce Biosciences, Inc.
Via Business Wire
Spruce Biosciences Reports Third Quarter 2021 Financial Results and Provides Corporate Updates
From Spruce Biosciences, Inc.
Via Business Wire
Spruce Biosciences Appoints Mike Grey as Interim CEO
From Spruce Biosciences, Inc.
Via Business Wire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.